Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-47,975
Closed -$2.51M – 2071
2026
Q2
$2.51M Sell
47,975
-4,042
-8% -$214K 0.01% 714
2026
Q1
$2.87M Buy
52,017
+5,006
+11% +$271K 0.01% 651
2025
Q4
$2.31M Buy
47,011
+5,975
+15% +$279K 0.01% 743
2025
Q3
$1.77M Buy
41,036
+24,952
+155% +$975K 0.01% 804
2025
Q2
$618K Buy
16,084
+4,824
+43% +$184K ﹤0.01% 1066
2025
Q1
$436K Buy
11,260
+1,693
+18% +$62K ﹤0.01% 1030
2024
Q4
$324K Buy
9,567
+910
+11% +$32.8K ﹤0.01% 997
2024
Q3
$354K Buy
8,657
+2,569
+42% +$105K ﹤0.01% 868
2024
Q2
$234K Buy
6,088
+11
+0.2% +$463 ﹤0.01% 870
2024
Q1
$261K Buy
+6,077
New +$251K ﹤0.01% 801
2022
Q3
– Sell
-4,075
Closed -$222K – 850
2022
Q2
$222K Buy
+4,075
New +$225K 0.01% 695

Other funds holding GSK

IEQ Capital's GSK Position: Q3 2026 in Review

IEQ Capital sold out of GSK (GSK) in Q3 2026, closing a stake of 47,975 shares — an estimated $2.51M sold.

IEQ Capital first reported a position in GSK in Q2 2022 and held it in 11 quarters. The position peaked at $2.87M in Q1 2026. 989 funds tracked by Wall St. Rank hold GSK as of Q3 2026.

  • IEQ Capital reported no remaining GSK position as of Q3 2026 after selling out during the quarter.
  • IEQ Capital sold 47,975 GSK shares in Q3 2026, an estimated $2.51M.
  • IEQ Capital first reported a position in GSK in Q2 2022 and held it in 11 quarters.
  • IEQ Capital's GSK position peaked at $2.87M in Q1 2026.
  • 989 funds tracked by Wall St. Rank held GSK as of Q3 2026.

Based on IEQ Capital's 13F filing for Q3 2026, filed 10 Nov 2026.